Patents Assigned to Prism BioLab Co., Ltd.
  • Publication number: 20230374034
    Abstract: A compound of the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof has a superior Notch signal transduction inhibitory action, and is useful for preventing or treating various diseases involving Notch signal transduction.
    Type: Application
    Filed: October 8, 2021
    Publication date: November 23, 2023
    Applicant: PRISM BIOLAB CO., LTD.
    Inventors: Hiroyuki KOUJI, Atsushi YOSHIMORI, Takenao ODAGAMI, Yoichiro HIROSE, Masaji KASHAI, Hajime TAKASHIMA, Eiji HONDA
  • Publication number: 20230265104
    Abstract: A compound of the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof has a superior inhibitory activity on cancer cell proliferation.
    Type: Application
    Filed: July 16, 2021
    Publication date: August 24, 2023
    Applicant: PRISM BIOLAB CO., LTD.
    Inventors: Hajime TAKASHIMA, Eiji HONDA, Tomonori TAGURI, Jun OZAWA, Haruyuki NISHIDA, Yoichiro HIROSE, Keisuke KIMURA
  • Patent number: 10017522
    Abstract: Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: July 10, 2018
    Assignee: PRISM BioLab Co., Ltd.
    Inventors: Takenao Odagami, Yuji Kogami, Hiroyuki Kouji
  • Patent number: 9682996
    Abstract: Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: June 20, 2017
    Assignee: PRISM BioLab Co., Ltd.
    Inventors: Hiroyuki Kouji, Yuji Kogami, Takenao Odagami
  • Patent number: 9126981
    Abstract: Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: September 8, 2015
    Assignee: PRISM BioLab Co., Ltd.
    Inventors: Hiroyuki Kouji, Yuji Kogami, Takenao Odagami
  • Patent number: 9040531
    Abstract: Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: May 26, 2015
    Assignee: PRISM BioLab Co., Ltd.
    Inventors: Takenao Odagami, Yuji Kogami, Hiroyuki Kouji
  • Publication number: 20120296067
    Abstract: Screening for low molecular weight compounds that regulate protein-protein interactions of a large number of proteins, including transcription factors, that have disordered sequences has been performed, but it has been almost impossible to obtain low molecular weight compounds having sufficient activity. The present inventors found that, regarding screening for a protein that regulates an interaction between an intrinsically disordered protein and a partner protein, carrying out screening while focusing on an disordered sequence, and selecting a candidate compound from peptidomimetic compounds that have a peptidomimetic backbone and have a peptide side chain or a side chain similar thereto enable a compound that regulates the activity of an intrinsically disordered protein to be efficiently selected, and the present inventors accomplished the present invention.
    Type: Application
    Filed: February 2, 2011
    Publication date: November 22, 2012
    Applicant: Prism BioLab Co., Ltd.
    Inventor: Hiroyuki Kouji